XXII Profile
22nd Century Group, Inc. is an agricultural biotechnology company dedicated to advancing tobacco harm reduction, developing reduced nicotine tobacco products, and improving health and wellness through plant science. The company's portfolio includes very low nicotine content tobacco products, marketed under the VLN King and VLN Menthol King brands, aimed at mitigating the health risks associated with nicotine consumption. Additionally, 22nd Century Group develops SPECTRUM research cigarettes, designed for use in clinical studies to evaluate the effects of reduced nicotine tobacco in controlled environments.
The company's research extends beyond tobacco, as it collaborates with Keygene N.V. to develop advanced hemp and cannabis plants. This collaboration focuses on creating plants with exceptional cannabinoid profiles and superior agronomic traits, catering to medical, therapeutic, and agricultural applications. This initiative reflects 22nd Century Group’s commitment to leveraging plant science to enhance product efficacy and sustainability in the life sciences and consumer products industries.
Founded in 1998 and headquartered in Buffalo, New York, 22nd Century Group has established itself as a leader in the intersection of biotechnology and tobacco harm reduction. The company's innovative approach addresses critical health challenges while also exploring new frontiers in plant-based therapies and agricultural biotechnology.
Through its strategic partnerships and research initiatives, 22nd Century Group aims to drive significant advancements in public health and wellness. The company continues to focus on integrating cutting-edge science with practical applications to deliver impactful solutions across its diverse product lines and research areas.
|
